Thanks all for the response and support.
I felt there are some big problems in IBD research, likely even beyond. The great efforts are not dedicated to solve the problem based on dynamic reasoning, but rather great resource has been spent to fulfill some miraculous fantasy generated by those capable.
As we know, IBD emerged and dramatically increased only for about a century, clearly suggesting factors in the environment have played the dominant role. However, tremendous efforts and resources have kept spending on genes and things within the body, with very little effort on finding out the causative factors in the environment. The identification of more and more risk genes for IBD in the last decade had served as examples of great achievements with many publications in the most prestigious journals [1]. However, the shadows behind these glories were well hidden that made hardly any people in the world even aware of their existence.
As we know, the association between NOD2 (also called IBD1 or CARD15) and Crohn's disease (CD) was first published in 2001 in Nature [2, 3]. It has been celebrated as a big breaking through in IBD. At beginning, it had estimated that NOD2 itself could explain 15 – 20 % of the genetic risk of CD [4, 5]. Later, 32 CD risk loci were identified in 2008 through genome wide association study (GWAS) but the new calculation suggested the 32 loci all together may just explain about 20% of the genetic risk, in which only about 1 – 2 % can be attributed to NOD2, despite that NOD2 has been the gene with the biggest contribution [6]. As it was esteemed that the genes may contribute 50% of the overall risk, the 32 loci all together may explain about 10% of the overall risk of CD [6]. A recent study that included more than 75,000 cases and controls has revealed 163 risk loci for IBD, including 140 loci for CD and 133 loci for ulcerative colitis (UC) [7]. However, they can only explain 13.6% of the overall disease risk for CD and 7.5% for UC [7]. Although more GWAS study would find more loci associated “significantly” with IBD, the association would be even weaker and the effect would be even smaller [8].
More importantly, those crucial genes identified by these studies seemed actually not that critical. The ultimate judgment of the importance of a gene would be to see how the disease develop after getting rid of the gene, which can be done by knockout a certain gene in the mice. In fact, shortly after finding NOD2 being an important risk gene for CD, NOD2 deficient mice were successfully generated, with the paper published in 2003 [9]. Surprisingly, it was found that mice lacking NOD2 were indistinguishable from controls and showed no signs of intestinal pathology. No NOD2 deficient mice had any obvious histological abnormalities in the colon, cecum, duodenum, or ileum. In 2006, GWAS revealed autophagy-related gene 16-like 1 (ATG16L1) being a susceptible gene for CD [10] and it generated a new round of enthusiasm on the critical role of autophagy, microbial sensing, endoplasmic reticulum stress in IBD [11]. However, no spontaneous (naturally occurred) colitis was developed in knockout mice deficient of ATG16L1 [12]. In 2006, another GWAS also identified IL23R as a risk gene for IBD gene[13] and the IL-23/IL17 axis has been expected a crucial pathway in IBD and became another area of extensive research [14]. However, it was found that IL-17 knockout mice developed more severe colitis caused by dextran sulfate sodium [15]. In fact, the recent randomized, double-blind placebo-controlled trial regarding the effect of the anti-IL-17A monoclonal antibody on CD has to be discontinued prematurely due to the higher rates of adverse events [16]. So, should the results of these genetic research in IBD serve as an example of great success or rather the great difficulty to make an accurate assessment of the true nature of a disease that was caused by factors in the environmental by just analysis of the genes and other factors within the body without knowing its cause?
Interestingly, this dubious hypothesis discussed here, based on evidence mainly collected from the literature during spare time and only accepted for publication by some low rank journals with the publishing fee paid by the author himself, was actually in good accordance with the results of the knockout mice. This hypothesis suggested a weakening of the mucus layer rather than the immune system or the gene being the root mechanism for IBD, which is strongly supported by the fact that mice either deficient of MUC2 [17], the main component of the mucus layer of the gut, or aberrant assembly of MUC2 [18], or just some defect in the mucin linked glycans [19] developed spontaneous colitis. However, MUC2 had not included in the 200 IBD associated genes identified by the multiple GWAS studies [7, 20]. You see, this vulgar hypothesis not only provided a simple explanation for many peculiar epidemiological features of IBD, it had also made a much better prediction on the importance of molecules associated with IBD than the many elegant genetic studies. Again, are they just coincidences?
As Einstein said: “time has a sieve” that will eventually make a selection among those splendid and important and those insipid and bad. There have been a lot facts gathered in the last decade and definitely more will emerge that would eventually show us which path would more likely leads to a final solution for IBD such as the understanding of its cause and root mechanism and ultimately its cure and prevention.
REFERENCES
1. Visscher, P.M., et al., Five years of GWAS discovery. Am J Hum Genet, 2012. 90(1): p. 7-24.
http://www.ncbi.nlm.nih.gov/pubmed/22243964
2. Hugot, J.P., et al., Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 2001. 411(6837): p. 599-603.
http://www.ncbi.nlm.nih.gov/pubmed/11385576
3. Ogura, Y., et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 2001. 411(6837): p. 603-6.
http://www.ncbi.nlm.nih.gov/pubmed/11385577
4. Marx, J., Biomedicine. Puzzling out the pains in the gut. Science, 2007. 315(5808): p. 33-5.
http://www.ncbi.nlm.nih.gov/pubmed/17204619
5. Torok, H.P., et al., Alterations of the CARD15/NOD2 gene and the impact on management and treatment of Crohn's disease patients. Dig Dis, 2003. 21(4): p. 339-45.
http://www.ncbi.nlm.nih.gov/pubmed/14752224
6. Barrett, J.C., et al., Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet, 2008. 40(8): p. 955-62.
http://www.ncbi.nlm.nih.gov/pubmed/18587394
7. Jostins, L., et al., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012. 491(7422): p. 119-24.
http://www.ncbi.nlm.nih.gov/pubmed/23128233
8. Park, J.H., et al., Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet, 2010. 42(7): p. 570-5.
http://www.ncbi.nlm.nih.gov/pubmed/20562874
9. Pauleau, A.L. and P.J. Murray, Role of nod2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol, 2003. 23(21): p. 7531-9.
http://www.ncbi.nlm.nih.gov/pubmed/14560001
10. Hampe, J., et al., A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet, 2007. 39(2): p. 207-11.
http://www.ncbi.nlm.nih.gov/pubmed/17200669
11. Kaser, A. and R.S. Blumberg, Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology, 2011. 140(6): p. 1738-47.
http://www.ncbi.nlm.nih.gov/pubmed/21530740
12. Saitoh, T., et al., Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature, 2008. 456(7219): p. 264-8.
http://www.ncbi.nlm.nih.gov/pubmed/18849965
13. Duerr, R.H., et al., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science, 2006. 314(5804): p. 1461-3.
http://www.ncbi.nlm.nih.gov/pubmed/17068223
14. Sarra, M., et al., IL-23/IL-17 axis in IBD. Inflamm Bowel Dis, 2010. 16(10): p. 1808-13.
http://www.ncbi.nlm.nih.gov/pubmed/20222127
15. Yang, X.O., et al., Regulation of inflammatory responses by IL-17F. J Exp Med, 2008. 205(5): p. 1063-75.
http://www.ncbi.nlm.nih.gov/pubmed/18411338
16. Hueber, W., et al., Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 2012. 61(12): p. 1693-1700.
http://www.ncbi.nlm.nih.gov/pubmed/22595313
17. Van der Sluis, M., et al., Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology, 2006. 131(1): p. 117-29.
http://www.ncbi.nlm.nih.gov/pubmed/16831596
18. Heazlewood, C.K., et al., Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med, 2008. 5(3): p. e54.
http://www.ncbi.nlm.nih.gov/pubmed/18318598
19. Fu, J., et al., Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest, 2011. 121(4): p. 1657-66.
http://www.ncbi.nlm.nih.gov/pubmed/21383503
20. Elding, H., et al., Refinement in Localization and Identification of Gene Regions Associated with Crohn Disease. Am J Hum Genet, 2012.
http://www.ncbi.nlm.nih.gov/pubmed/23246291